Haba T, Mabuchi H, Yoshimura A, Watanabe A, Wakasugi T, Tatami R, Ueda K, Ueda R, Kametani T, Koizumi J, Miyamoto S, Takeda R, Takeshita H
J Clin Invest. 1981 May;67(5):1532-40. doi: 10.1172/jci110184.
We studied biochemical genetics of low density lipoprotein (LDL) receptor mutations in fibroblasts from six homozygous and five heterozygous patients with familial hypercholesterolemia (FH). Three of six homozygotes are receptor-negative type and the other three homozygotes are receptor-defective type. In the cells from three receptor-negative homozygotes, the receptor binding, internalization, and degradation of (125)I-LDL were 0.5+/-0.3 ng/mg protein (mean+/-SEM), 14+/-8 and 8+/-6 ng/mg protein per 6 h (four normal cells; 44+/-3, 386+/-32, and 1,335+/-214 ng/mg protein per 6 h), respectively. In the cells from three receptor-defective homozygotes, the receptor binding, internalization, and degradation of (125)I-LDL were 6+/-2, 29+/-8, and 90+/-32 ng/mg protein per 6 h, respectively. In these six homozygotes, two pairs of siblings are included. Two siblings in the same family were classified as receptor-negative and two siblings in another family were classified as receptor-defective. The receptor-negative phenotypes and the receptor-defective phenotypes bred true in individual families. The cells from five heterozygotes showed approximately 46% of the normal activities of receptor.ML-236B, competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), completely inhibited the incorporation of [(14)C]acetate into digitonin-precipitable sterols in fibroblasts from normal subjects and heterozygous and homozygous patients with FH with the concentration of 0.5 mug/ml. However, at 0.05 mug/ml of ML-236B sterol synthesis in fibroblasts from homozygotes was not completely suppressed in contrast to normal and heterozygous cells. Moreover, after preincubation with 0.05 mug/ml of ML-236B for 24 h in medium containing lipoproteins, sterol synthesis in the cells from receptor-negative homozygote showed 75% of the initial activity compared with that of 25% without preincubation. In the cells from a normal subject and a heterozygote, sterol synthesis was inhibited even after preincubation. These results suggest that (a) the inhibitory effect of ML-236B is overcome in homozygote cells by their high intracellular levels of HMG-CoA reductase and (b) that a higher dose of ML-236B may be required to lower serum cholesterol levels in FH homozygotes than in heterozygotes.
我们研究了6名纯合子和5名杂合子家族性高胆固醇血症(FH)患者成纤维细胞中低密度脂蛋白(LDL)受体突变的生化遗传学。6名纯合子中有3名是受体阴性型,另外3名纯合子是受体缺陷型。在3名受体阴性纯合子的细胞中,(125)I-LDL的受体结合、内化和降解分别为0.5±0.3 ng/mg蛋白质(平均值±标准误)、每6小时14±8 ng/mg蛋白质和每6小时8±6 ng/mg蛋白质(4个正常细胞;每6小时分别为44±3、386±32和1335±214 ng/mg蛋白质)。在3名受体缺陷纯合子的细胞中,(125)I-LDL的受体结合、内化和降解分别为每6小时6±2、29±8和90±32 ng/mg蛋白质。在这6名纯合子中,包括两对兄弟姐妹。同一家庭的两名兄弟姐妹被分类为受体阴性,另一个家庭的两名兄弟姐妹被分类为受体缺陷。受体阴性表型和受体缺陷表型在各个家族中均能稳定遗传。5名杂合子的细胞显示出约46%的正常受体活性。ML-236B是3-羟基-3-甲基戊二酰辅酶A还原酶(HMG-CoA还原酶)的竞争性抑制剂,在浓度为0.5μg/ml时,能完全抑制正常受试者以及FH杂合子和纯合子患者成纤维细胞中[(14)C]乙酸掺入洋地黄皂苷可沉淀的固醇中。然而,与正常细胞和杂合子细胞相比,在0.05μg/ml的ML-236B作用下,纯合子成纤维细胞中的固醇合成并未被完全抑制。此外,在含脂蛋白的培养基中用0.05μg/ml的ML-236B预孵育24小时后,受体阴性纯合子细胞中的固醇合成与未预孵育时相比,显示出初始活性的75%。在正常受试者和杂合子的细胞中,即使经过预孵育,固醇合成也受到抑制。这些结果表明:(a)ML-236B的抑制作用在纯合子细胞中被其细胞内高水平的HMG-CoA还原酶所克服;(b)与杂合子相比,FH纯合子可能需要更高剂量的ML-236B才能降低血清胆固醇水平。